Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366997 | 1.00 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL4175709 | 0.96 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL19953615 | 0.93 | PTGS2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL8289160 | 0.93 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL4191070 | 0.92 | PTGS2 (0.42) | PTGS2PTGS1 | |
| SCHEMBL4197238 | 0.92 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL4179563 | 0.92 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL4185483 | 0.90 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL4190197 | 0.89 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL8289110 | 0.89 | MCHR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | claimed |
| US-20200383983-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | ALLERGAN SALES, LLC | 2020-12-10 | — | — | US | claimed |
| WO-2020214906-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | ALLERGAN SALES, LLC (US) | 2020-10-22 | — | — | WO | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| US-20130231311-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2013-09-05 | — | — | US | claimed |
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | claimed |
| EP-2444086-A1 | Combinations comprising DHODH inhibitors and COX inhibitors | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| US-20110118189-A1 | NOVEL FORMULATIONS FOR TREATMENT OF MIGRAINE | ZOGENIX, INC. | 2011-05-19 | — | — | US | claimed |
| WO-2002015884-A2 | RAPIDLY DISINTEGRATING ORAL FORMULATION OF A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2002-02-28 | — | — | WO | claimed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | claimed |
| WO-2002005815-A1 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2002005848-A2 | USE OF COX-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF OCULAR COX-2 MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2002-01-24 | — | — | WO | claimed |
| US-20020009421-A1 | Therapy following skin injury from exposure to ultraviolet radiation | PHARMACIA CORPORATION | 2002-01-24 | — | — | US | claimed |
| WO-2001091856-A2 | USE OF COX2 INHIBITORS FOR TREATING SKIN INJURY FROM EXPOSURE TO ULTRAVIOLET RADIATION | PHARMACIA CORPORATION (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001078724-A1 | RAPID-ONSET FORMULATION OF A SELECTIVE CYCLOOXIGENASE-2 | PHARMACIA CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | claimed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | claimed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | PTGS2 32/4885PTGS1 15/4885 |
| US-20020009421-A1 | Therapy following skin injury from exposure to ultraviolet radiation | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | PTGS2 3/4885PTGS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.